Cervical cancer screening in Switzerland: time to rethink the guidelines

Pierre Vassilakos; Rosa Catarino; Brigitte Frey Tirri; Patrick Petignat

doi:10.4414/smw.2015.14112

Technical comment

Vol. 145 No. 0708 (2015)

Cervical cancer screening in Switzerland: time to rethink the guidelines

Pierre Vassilakos
Rosa Catarino
Brigitte Frey Tirri
Patrick Petignat

DOI: https://doi.org/10.4414/smw.2015.14112
Cite this as:: Swiss Med Wkly. 2015;145:w14112
Published: 08.02.2015

References

Petignat P, Untiet S, Vassilakos P. How to improve cervical cancer screening in Switzerland? Swiss Med Wkly. 2012;142:w13663 http://www.smw.ch/content/smw-2012-13663.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32.
Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97.
Bulkmans N, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72.
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.
Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672–82.
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.
Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee Fung M, Gzik D, et al. HPV testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2012;34(5):443–52.
Arbyn M, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–F99.
Health Council of the Netherlands. Population screening for cervical cancer. http://www.gezondheidsraad.nl/en/publications/prevention/population-screening-cervical-cancer (2011) (accessed April 28, 2014).
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–72.
U.S. Food and Drug Administration (FDA). FDA approves first human papillomavirus test for primary cervical cancer screening. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394773.htm. (accessed April 24, 2014).
Elfström KM, Smelov V, Johansson AL, Eklund C, Nauclér P, Arnheim-Dahlström L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;348.
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–72.
Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864–71.
Australian Government. MSCA. Application No. 1276 – Renewal of the National Cervical Screening Program. (2014, April 3–4). Retrieved November 4, 2014, from http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20–%20Final%20MSAC%20PSD%20–%20NCSP%20Renewal.pdf http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276 – Final MSAC PSD – NCSP Renewal.pdf.
Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88–99.
Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20.

How to Cite

1.

Vassilakos P, Catarino R, Frey Tirri B, Petignat P. Cervical cancer screening in Switzerland: time to rethink the guidelines. Swiss Med Wkly [Internet]. 2015 Feb. 8 [cited 2024 Apr. 20];145(0708):w14112. Available from: https://smw.ch/index.php/smw/article/view/2009

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Pierre Vassilakos, Phuong Lien Tran, Roland Sahli, Nicola Low, Patrick Petignat, HPV-negative CIN3 and cervical cancer in Switzerland: any evidence of impact on screening policies? , Swiss Medical Weekly: Vol. 147 No. 4748 (2017)
Aurore Fehlmann, Khadidja Benkortbi, Ginette Rosseel, Ulrike Meyer-Hamme, Jean-Christophe Tille, Frédérique Sloan-Béna, Ariane Paolini-Giacobino, Anne-Laure Rougemont, Alexandre Bodmer, Diomidis Botsikas, Patrice Mathevet, Patrick Petignat, Manuela Undurraga Malinverno, Gestational trophoblastic disease in Switzerland: retrospective study of the impact of a regional reference centre , Swiss Medical Weekly: Vol. 151 No. 0506 (2021)
Pierre Vassilakos, Rosa Catarino, Michel Boulvain, Patrick Petignat, Controversies in the mammography screening programme in Switzerland , Swiss Medical Weekly: Vol. 144 No. 1718 (2014)
Marc Blondon, Françoise Boehlen, Pierre Fontana, Patrick Petignat, Genetic testing to identify women at risk of venous thromboembolism with contraceptive pills: evidence- or hope-based tool? , Swiss Medical Weekly: Vol. 146 No. 2122 (2016)
Patrick Petignat, Sarah Untiet, Pierre Vassilakos, How to improve cervical cancer screening in Switzerland? , Swiss Medical Weekly: Vol. 142 No. 3334 (2012)
Alessandra Vanetti, Rosa Catarino, Michal Yaron, Remote self-assessment follow-up for medical termination of pregnancy at Geneva University Hospitals: an insight into its acceptability, success rate and costs , Swiss Medical Weekly: Vol. 151 No. 2930 (2021)

[1] Petignat P, Untiet S, Vassilakos P. How to improve cervical cancer screening in Switzerland? Swiss Med Wkly. 2012;142:w13663 http://www.smw.ch/content/smw-2012-13663.

[2] Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32.

[3] Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97.

[4] Bulkmans N, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72.

[5] Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.

[6] Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672–82.

[7] Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.

[8] Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee Fung M, Gzik D, et al. HPV testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2012;34(5):443–52.

[9] Arbyn M, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–F99.

[10] Health Council of the Netherlands. Population screening for cervical cancer. http://www.gezondheidsraad.nl/en/publications/prevention/population-screening-cervical-cancer (2011) (accessed April 28, 2014).

[11] Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–72.

[12] U.S. Food and Drug Administration (FDA). FDA approves first human papillomavirus test for primary cervical cancer screening. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394773.htm. (accessed April 24, 2014).

[13] Elfström KM, Smelov V, Johansson AL, Eklund C, Nauclér P, Arnheim-Dahlström L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;348.

[14] Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337.

[15] Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–72.

[16] Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864–71.

[17] Australian Government. MSCA. Application No. 1276 – Renewal of the National Cervical Screening Program. (2014, April 3–4). Retrieved November 4, 2014, from http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20–%20Final%20MSAC%20PSD%20–%20NCSP%20Renewal.pdf http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276 – Final MSAC PSD – NCSP Renewal.pdf.

[18] Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88–99.

[19] Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20.